Please assess the completion status of the following clinical trial:

Trial Title: GM1 Prophylaxis for WBRT Related Cognitive Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18-75,with histological affirmative breast cancer ,and over 4 brain metastases ,need for WBRT suggested by radiotherapy oncologist ;~* Estimated survival time over 6months;~* Abundant hematological function:Absolute Neutrophil Count≥2×109/L ;platelet count≥100×109/L and hemoglobulin≥9 g/dL;~* Abundant liver function：total bilrubin≤ULN；ASTandALT≤2.5ULN；AKP≤5ULN~* Can cope with HVLT-RDR and ADAS-Cog evaluation~* No prior therapy could induce neurological damage,within 4 weeks~* No more that 1 degree peripheral neuropathy or any other diseases or symptoms that could hinder the evaluation of neurological AE~* No more treatment or nursing is allowed after enrolling this trail~* Written Informed Consent signed~Exclusion Criteria:~* PS score over 2,and estimated no attenuation by WBRT~* Women with pregnancy or breast feeding~* Unwilling to contraception measurement~* Abnormal baseline impairment of cognitive impairment~* Allergy to experiment agents or components~* Unsuitable to GM1 treatment, evaluated by investigators~* Active infection~* RT dose over 30Gy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Experimental arm(GM1) (Type: EXPERIMENTAL): This arm will be treated with GM1.
- Control arm (Type: PLACEBO_COMPARATOR): This arm will be treat with blank placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).